Please ensure Javascript is enabled for purposes of website accessibility

Here's Why NantKwest's Shares Got Clobbered in August

By George Budwell - Sep 11, 2015 at 2:20PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

NantKwest's shares were hammered by a turbulent market in August.

NK Chart

NK data by YCharts.

What: Shares of NantKwest (NK), a clinical-stage immunotherapy company focusing on the use of natural killer cells to treat cancer, plunged by 44% in August, according to data from S&P Capital IQ, making it one of the worst-performing biotechs/biopharmas during the month. 

So what: NantKwest picked perhaps the worst time in recent memory to execute an initial public offering, at least from standpoint of an investor. Hoping to cash in on the healthcare IPO bonanza that has raised tons of cash for early clinical trial-stage companies of late, NantKwest went public in late July.

At first, demand for the company's shares was unusually strong, with the stock pushing past $38 a share -- up from the initial price of $25. Unfortunately, NantKwest's shares have since fallen by approximately 53% from those former highs, falling prey to the widespread August sell-off that hit clinical-stage biopharmas particularly hard.

Now what: NantKwest is gearing up to test its immunotherapy platform across a host of virally induced solid tumors and a handful of hematological malignancies at the mid-stage level. If the the company can get these trials enrolled in time, we'll most likely get an update on their status at next year's American Society of Clinical Oncology meeting. Until then, however, I'm satisfied to watch this biopharma from the sidelines, given how badly the market has treated these types of stocks lately. 

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

NantKwest, Inc. Stock Quote
NantKwest, Inc.

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/28/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.